The FDA approved its first biosimilar indicated for multiple sclerosis (MS), Sandoz’ Tyruko (natalizumab-sztn), a biosimilar referencing Tysabi (natalizumab).
The FDA approved Tyruko (natalizumab-sztn), a natalizumab biosimilar, as a monotherapy for multiple sclerosis (MS), making it the first neurology biosimilar to receive regulatory approval in the United States.
The product was developed by Polpharma Biologics and will be marketed by Sandoz as a part of a commercialization agreement. Tyruko was approved for all indications of the reference product (Tysabri). Natalizumab is an anti- integrin monoclonal antibody disease-modifying treatment and can be used to treat clinically isolated syndrome, relapsing-remitting MS, active secondary progressive disease, and Crohn disease in adults.
The biosimilar also has the same intravenous dosage form, route of administration, dosing regimen, and presentation as the reference product.
“Of the nearly one million people in the US living with multiple sclerosis, hundreds of thousands experience disease relapse. Tyruko has the potential to extend the reach of natalizumab treatment for these patients, increase healthcare savings and fuel innovation through competition in the market,” Keren Haruvi, president North America, Sandoz, said in a statement.
Sandoz originally submitted a biologics license application for Tyruko in 2022 and announced its plans to commercialize a natalizumab biosimilar in September 2019. Under the global commercialization agreement for Tyruko, Polpharma Biologics will maintain responsibility for development, manufacturing, and supply of the active substance in Tyruko, and Sandoz has the rights to commercialize and distribute it in all markets.
In November 2019, Polpharma Biologics began its phase 3 clinical trial assessing the safety and efficacy of Tyruko, then known as PB006, compared with the reference agent.
Polpharma published the results showing the biosimilarity between the products in January 2023. The parallel-group, randomized, active-controlled Antelope trial included patients from 48 centers across 7 countries, and the results supported the use of PB006 as an adequate alternative to the reference product.
In addition to Tyruko being the first and only biosimilar approved to treat relapsing forms of MS, there are no MS biosimilars approved in the European Union, Canada, or Australia. In April 2023, IQVIA released a report that found that neurologists in Europe are well aware of the biosimilar pipeline for MS and are planning to use them to expand treatment access for their patients.
The main generic and biosimilar drugs for MS expected to launch over the next 5 years are estimated to generate between €4.5 billion to €5.5 billion in savings between 2023 and 2028 in France, Germany, Italy, Spain, and the United Kingdom.
“Access to affordable, high-quality health care is essential for people with multiple sclerosis to live their best lives. The approval of Tyruko, the first FDA-approved biosimilar disease-modifying treatment for people with relapsing forms of MS, is a milestone. Biosimilars are an important treatment option because they have no clinically meaningful differences from their reference medicines. Prescribing them can increase accessibility to affordable medications, improve adherence and help contain healthcare costs,” Bari Talente, executive vice president for advocacy and health care access at the National MS Society, said in the statement.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Health Canada Approves First Omalizumab Biosimilar
December 16th 2024Health Canada has approved Omlyclo, the first omalizumab biosimilar in Canada, for the treatment of chronic idiopathic urticaria, allergic asthma, and chronic rhinosinusitis with nasal polyps, based on a phase 3 study confirming its bioequivalence to the reference product.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
BioRationality: Withdrawal of Proposed Terminal Disclaimer Rule Spells Major Setback for Biosimilars
December 10th 2024The United States Patent and Trademark Office (USPTO)’s withdrawal of its proposed terminal disclaimer rule is seen as a setback for biosimilar developers, as it preserves patent prosecution practices that favor originator companies and increases costs for biosimilar competition, according to Sarfaraz K. Niazi, PhD.
Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration
December 10th 2024Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for denosumab biosimilars, and Intas Pharmaceuticals partnered with Xbrane Biopharma on a nivolumab biosimilar.